Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes

REFERENCES

• Wide-ranging online data for epidemiologic research (WONDER). In: Control UCfD, ed. Atlanta, GA 2015.
   Google Scholar
• Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA internal medicine. 2015;175(4):608–615.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Zhang K, Jones CM, Mack KA. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. Journal of the American Board of Family Medicine: JABFM. 2014;27(3):329–338.
   PubMed Web of Science ®Google Scholar
• King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990–2013: a systematic review. Am J Public Health. 2014;104(8):e32–42.
   PubMed Web of Science ®Google Scholar
• Bohnert AS, Logan JE, Ganoczy D, Dowell D. A Detailed Exploration Into the Association of Prescribed Opioid Dosage and Overdose Deaths Among Patients With Chronic Pain. Med Care. 2016;54(5):435–441.
   PubMed Web of Science ®Google Scholar
• Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. Jama. 2011;305(13):1315–1321.
   PubMed Web of Science ®Google Scholar
• Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med. 2016;17(1):85–98.
   PubMed Web of Science ®Google Scholar
• Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92.
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686–691.
   PubMed Web of Science ®Google Scholar
• Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA internal medicine. 2014;174(5):796–801.
   PubMed Web of Science ®Google Scholar
• Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: role for both daily and total opioid dose? The journal of pain: official journal of the American Pain Society. 2015;16(4):318–325.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med. 2012;13(1):87–95.
   PubMed Web of Science ®Google Scholar
• Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med. 2014;15(11):1911–1929.
   PubMed Web of Science ®Google Scholar
• Common Elements in Guidelines for Prescribing Opioids for Chronic Pain. http://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf Accessed July 11, 2016.
   Google Scholar
• Franklin G, Sabel J, Jones CM, et al. A comprehensive approach to address the prescription opioid epidemic in Washington State: milestones and lessons learned. Am J Public Health. 2015;105(3):463–469.
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Bauer AM, Fulton-Kehoe D, et al. Trends in Opioid Dosing Among Washington State Medicaid Patients Before and After Opioid Dosing Guideline Implementation. The journal of pain: official journal of the American Pain Society. 2016.
   PubMed Web of Science ®Google Scholar
• Keast SL, Farmer K, Smith M, Nesser N, Harrison D. Prior authorization policies in Medicaid programs: The importance of study design and analysis on findings and outcomes from research. Research in social & administrative pharmacy: RSAP. 2016;12(1):154–163.
   PubMed Web of Science ®Google Scholar
• Morden NE, Zerzan JT, Rue TC, et al. Medicaid prior authorization and controlled-release oxycodone. Med Care. 2008;46(6):573–580.
   Google Scholar
• Garcia MM, Angelini MC, Thomas T, Lenz K, Jeffrey P. Implementation of an opioid management initiative by a state Medicaid program. Journal of managed care & specialty pharmacy. 2014;20(5):447–454.
   PubMed Web of Science ®Google Scholar
• Oregon Medicaid Fee-For-Service Prior Authorization Criteria. 2012; http://www.oregon.gov/oha/healthplan/tools/Oregon%20Medicaid%20PA%20Criteria,%20June%202012.pdf. Accessed February 27, 2017.
   Google Scholar
• Hartung DM, Zerzan J, Yamashita T, Tong S, Morden NE, Libby AM. Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs. Pharmacoepidemiol Drug Saf. 2014;23(1):87–94.
   PubMed Web of Science ®Google Scholar
• National Center for Injury Prevention and Control. CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2016 version. 2016; http://www.pdmpassist.org/pdf/BJA_performance_measure_aid_MME_conversion.pdf. Accessed March 23, 2017.
   Google Scholar
• Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. Am J Manag Care. 2013;19(8):648–665.
   PubMed Web of Science ®Google Scholar
• Peirce GL, Smith MJ, Abate MA, Halverson J. Doctor and pharmacy shopping for controlled substances. Med Care. 2012;50(6):494–500.
   PubMed Web of Science ®Google Scholar
• Fulton-Kehoe D, Sullivan MD, Turner JA, et al. Opioid poisonings in Washington State Medicaid: trends, dosing, and guidelines. Med Care. 2015;53(8):679–685.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA internal medicine. 2015;175(6):978–987.
   PubMed Web of Science ®Google Scholar
• Ai C, Norton EC. Standard errors for the retransformation problem with heteroscedasticity. Journal of health economics. 2000;19(5):697–718.
   PubMed Web of Science ®Google Scholar
• Stuart EA, Huskamp HA, Duckworth K, et al. Using propensity scores in difference-in-differences models to estimate the effects of a policy change. Health services & outcomes research methodology. 2014;14(4):166–182.
   PubMedGoogle Scholar
• Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–759.
   PubMed Web of Science ®Google Scholar
• Frakt AB, Bagley N. Protection or Harm? Suppressing Substance-Use Data. N Engl J Med. 2015;372(20):1879–1881.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wilsey B, Bohm M, et al. Defining risk of prescription opioid overdose: pharmacy shopping and overlapping prescriptions among long-term opioid users in medicaid. The journal of pain: official journal of the American Pain Society. 2015;16(5):445–453.
   PubMed Web of Science ®Google Scholar
• Ross JS, Jackevicius C, Krumholz HM, et al. State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. Health affairs (Project Hope). 2012;31(1):188–198.
   PubMed Web of Science ®Google Scholar
• Reinke T. Prior authorization for safety, not just for economy. Manag Care. 2012;21(12):33–35.
   Google Scholar
• Garg RK, Fulton-Kehoe D, Turner JA, et al. Changes in opioid prescribing for Washington workers' compensation claimants after implementation of an opioid dosing guideline for chronic noncancer pain: 2004 to 2010. The journal of pain: official journal of the American Pain Society. 2013;14(12):1620–1628.
   PubMed Web of Science ®Google Scholar
• Fulton-Kehoe D, Garg RK, Turner JA, et al. Opioid poisonings and opioid adverse effects in workers in Washington state. American journal of industrial medicine. 2013;56(12):1452–1462.
   PubMed Web of Science ®Google Scholar
• Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in Drug and Opioid Overdose Deaths–United States, 2000–2014. MMWR Morbidity and mortality weekly report. 2016;64(50-51):1378–1382.
   PubMed Web of Science ®Google Scholar
• Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths – United States, 2010–2015. MMWR Morbidity and mortality weekly report. 2016;65(5051):1445–1452.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Farley JF, Holmes GM, et al. Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy. Health affairs (Project Hope). 2016;35(10):1884–1892.
   PubMed Web of Science ®Google Scholar
• Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev. 2010(8):Cd008654.
   PubMed Web of Science ®Google Scholar
• Weimer MB, Hartung DM, Ahmed S, Nicolaidis C. A chronic opioid therapy dose reduction policy in primary care. Subst Abus. 2016;37(1):141–147.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. Jama. 2016;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Ziegler SJ. The Proliferation of Dosage Thresholds in Opioid Prescribing Policies and Their Potential to Increase Pain and Opioid-Related Mortality. Pain Med. 2015;16(10):1851–1856.
   PubMed Web of Science ®Google Scholar
• Tavernise S. C.D.C. Painkiller Guidelines Aim to Reduce Addiction Risk. New York Times. March 15, 2016, 2016.
   Google Scholar
• Oregon Health Authority. Back Conditions Technical Changes 2016; http://www.oregon.gov/oha/herc/FactSheet/Back-line-and-guideline-tech-summary.pdf. Accessed March 22, 2017.
   Google Scholar
• Kertesz SG. Turning the tide or riptide? The changing opioid epidemic. Substance Abuse. 2017;38(1):3–8.
   PubMed Web of Science ®Google Scholar